Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Qi-Chao Bao"'
Autor:
Nan Wang, Zheng-Yu Jiang, Xingyang Gao, Weikang Yang, Qi-Chao Bao, Liangying Zhang, Qidong You, Brian Gabet
Publikováno v:
ACS Med Chem Lett
[Image: see text] Selective inhibition of Janus kinases (JAKs) is an arising strategy in drug discovery. Covalent inhibitors targeting a unique cysteine in JAK3 exhibit ultraselectivity among JAK family members. However, safety and tissue specific co
Autor:
Wei-Lin Chen, Lixiao Zhang, Lei Wang, Qidong You, Chengxiang Wang, Jingsheng Jiang, Li Li, Jialin Shang, Zheng-Yu Jiang, Qi-Chao Bao, Zhen Zheng, Jian Zhang, Xiao-Li Xu
Publikováno v:
Science Advances
Directly disrupting the Hsp90-Cdc37 complex can selectively down-regulate kinase clients of Hsp90 and achieve cell cycle arrest.
Disrupting the interactions between Hsp90 and Cdc37 is emerging as an alternative and specific way to regulate the H
Disrupting the interactions between Hsp90 and Cdc37 is emerging as an alternative and specific way to regulate the H
Autor:
Qi-Dong You, Qi-Chao Bao, Hui-Jie Wang, Fen Jiang, Qiong Zhang, Lei Wang, Di Jiang, Yu-Hui Jin, Xiao-Li Xu
Publikováno v:
Bioorganic & Medicinal Chemistry. 24:5431-5439
Heat shock protein 90 (Hsp90) as a molecular target for oncology therapeutics has attracted much attention in the last decade. The Hsp90 multichaperone complex has important roles in the growth and/or survival of cancer cells. Cdc37, as a cochaperone
Publikováno v:
RSC Advances. 6:56738-56746
RhoA has been implicated in diverse cellular functions and is a potential cancer therapeutic target. Through virtual screening, we have identified a RhoA inhibitor, DDO-5701. DDO-5701 has an affinity to RhoA at the micromolar level in vitro. By struc
Autor:
Qidong You, Fang Liu, Xiaojin Zhang, Haopeng Sun, Lu Wang, Qi-Chao Bao, Guo Xiaoke, Lei Wang, Fen Jiang, Xiao-Li Xu
Publikováno v:
RSC Advances. 6:42537-42544
CDC37 has emerged as a promising target in antitumor chemotherapy because of its significant role in oncogenic signaling networks. In an effort to discover novel CDC37 inhibitors, a shape-based model derived from celastrol was built. A high-throughpu
Autor:
Xiaojin Zhang, Xiao-Li Xu, Li-Li Xu, Guo Xiaoke, Meng-Chen Lu, Jinlian Wei, Qi-Chao Bao, Haopeng Sun, Zheng-Yu Jiang, Ying-Rui Yang, Fang Liu, Zhenwei Yuan, Qidong You
Publikováno v:
Scopus-Elsevier
p53 protein is a prominent tumor suppressor to induce cell cycle arrest, apoptosis and senescence, which attracts significant interest to cancer treatment. Therefore, it would be particularly important to restore the wild-type p53 that retains latent
Autor:
Qi-Chao Bao, Haopeng Sun, Yue Wu, Xingsen Wu, Qidong You, Hua Xia, Tianhan Hu, Lianshan Zhang, Yonghua Lei, Xiaojin Zhang
Publikováno v:
ACS Medicinal Chemistry Letters. 6:1236-1240
Prolyl hydroxylase domain 2 (PHD2) enzyme, a Fe(II) and 2-oxoglutarate (2-OG) dependent oxygenase, mediates key physiological responses to hypoxia by modulating the levels of hypoxia inducible factor 1-α (HIF1α). PHD2 has been shown to have the the
Autor:
Xiaojin Zhang, Xiao-Li Xu, Haopeng Sun, Kai Gu, Fen Jiang, Qidong You, Lei Wang, Guo Xiaoke, Qi-Chao Bao, Zheng-Yu Jiang
Publikováno v:
RSC Advances. 5:96138-96145
As an attractive anticancer target, the Hsp90 chaperone machine regulates a wide range of oncoproteins. Most of the Hsp90 inhibitors in clinical trials employ the same ATP blockage mechanism while little progress has been achieved with Hsp90–cochap
Autor:
Xiao-Li Xu, Haopeng Sun, Yonghua Lei, Taotao Feng, Guo Xiaoke, Wei-Lin Chen, Qidong You, Hongzhi Lin, Xiaojin Zhang, Qi-Chao Bao, Dong-Dong Li, Fang Liu
Publikováno v:
RSC Advances. 5:82936-82946
We present a hierarchical workflow combining shape- and electrostatic-based virtual screening for the identification of novel Jumonji domain-containing protein 2A (JMJD2A) inhibitors. Our virtual screening protocol initially involved the identificati
Autor:
Hui-Jie Wang, Fang Liu, Qi-Chao Bao, Jian-Min Jia, Lei Wang, Dong-Dong Li, Qi-Dong You, Zhi-Hui Wang, Yu-Hui Jin, Xiao-Li Xu, Qiong Zhang, Fen Jiang
Publikováno v:
Journal of medicinal chemistry. 59(23)
Heat shock protein 90 (Hsp90) is a potential target for oncology therapeutics. Some inhibitors have shown antitumor effects in clinical trials, spurring the discovery of small molecule Hsp90 inhibitors. Here, we describe the structural optimization s